Table 3.

Baseline characteristics of patients with metastatic NSCLC with EGFR mutations treated with EGFR-TKI

All (n = 34)Exon 19 deletion (n = 23)L858R (n = 11)P
Age
    Median646064
    Range41-8041-7448-80
Sex
    Female2011 (48%)9 (82%)0.08
    Male1412 (52%)2 (18%)
Smoking
    Former/Current1811 (48%)6 (55%)1.00
    Never1612 (52%)5 (45%)
Histology
    Adenocarcinoma189 (39%)9 (81%)0.11
    AWBF108 (35%)2 (18%)
    BAC33 (13%)0 (0%)
    Other33 (13%)0 (0%)
KPS at start of TKI
    80-100%2215 (65%)7 (64%)0.91
    60-70%53 (13%)2 (18%)
    not recorded75 (22%)2 (18%)
Prior chemotherapy
    01610 (44%)6 (55%)1.00
    1107 (30%)3 (27%)
    243 (13%)1 (9%)
    ≥343 (13%)1 (9%)
Drug received
    Erlotinib128 (35%)4 (36%)1.00
    Gefitinib2215 (65%)7 (64%)
Metastatic sites
    Bone119 (39%)2 (18%)0.53
    Brain55 (22%)0 (0%)
    Liver44 (17%)0 (0%)
    Other extrathoracic22 (9%)0 (0%)
  • Abbreviations: BAC, bronchioloalveolar carcinoma; AWBF, adenocarcinoma with bronchioloalveolar carcinoma features; KPS, Karnofsky performance status.